The global monkeypox (mpox) diagnosis market is anticipated to experience steady growth, projected to increase from an estimated US$1.95 billion in 2024 to US$2.4 billion by 2031, at a compound annual growth rate (CAGR) of 4.4% during the forecast period from 2024 to 2031. The rise in monkeypox cases, heightened awareness, and significant advancements in diagnostic technologies are key drivers for the market’s expansion. This article provides a comprehensive analysis of the market, covering its dynamics, regional insights, competitive landscape, and future outlook.
Market Size & Share Analysis
The monkeypox (mpox) diagnosis market has gained substantial momentum due to the increase in outbreaks globally, particularly following the spike in cases observed in 2022 and 2023. The World Health Organization (WHO) reported a global surge in monkeypox cases during these years, spurring demand for diagnostic tests. In 2024, the market is expected to generate US$1.95 billion, with North America accounting for approximately 41% of the market share, reflecting the region’s strong healthcare infrastructure and significant investment in diagnostic R&D. By 2031, the market size is expected to grow to US$2.4 billion, propelled by ongoing demand for precise diagnostic tools.
Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/34755
Key Industry Highlights
Several trends are shaping the monkeypox diagnosis market:
Expansion of Point-of-Care Testing (POCT): The growing need for quick, accurate, and decentralized diagnostic solutions is driving the expansion of POCT. This is particularly vital for detecting monkeypox in remote areas where laboratory infrastructure may be scarce.
Technological Advancements: The market is benefiting from innovations in molecular diagnostic tools, such as real-time PCR and next-generation sequencing, which have improved diagnostic accuracy and speed.
Rising Global Awareness and Surveillance: Increased public health efforts and surveillance systems post-2022 outbreaks have underscored the importance of early detection and robust diagnostic systems, which has been a key driver for market growth.
Market Dynamics
Driver: Increased Global Awareness and Surveillance
The 2022 monkeypox outbreak significantly raised global awareness about the disease, especially in high-risk regions. Governments and health organizations worldwide recognized the importance of early detection and monitoring systems to contain the virus. This global focus has triggered investments in diagnostic infrastructure and the widespread availability of testing kits, fueling demand across both developed and emerging markets.
Restraint: Limited Awareness and Testing Infrastructure in Developing Regions
Despite heightened awareness, many developing regions still lack the necessary infrastructure to effectively diagnose monkeypox. Issues like insufficient healthcare facilities, lack of trained personnel, and limited public health funding remain substantial barriers. These challenges can hamper the accessibility of diagnostic tools in areas where monkeypox outbreaks are more likely to occur.
Opportunity: Expansion of Point-of-Care Testing (POCT)
POCT offers a significant opportunity for growth in the monkeypox diagnosis market. The ability to provide diagnostic results in real-time, especially in resource-limited or remote areas, is crucial for managing outbreaks effectively. The growing development of portable, user-friendly diagnostic kits will enable rapid testing and improve response times, creating a more efficient healthcare system for managing infectious diseases.
Category-wise Analysis
Diagnostic Test: Molecular Test Dominates
In 2024, the molecular test segment is expected to dominate the monkeypox (mpox) diagnosis market, accounting for 57% of the total market share. This category includes advanced techniques such as polymerase chain reaction (PCR) tests, which are known for their high accuracy in detecting the genetic material of the monkeypox virus. PCR tests are widely considered the gold standard for diagnosing viral infections, providing a reliable and sensitive method for detecting the monkeypox virus.
Sample: Skin Lesion Specimen
Skin lesion specimens are expected to account for 63% of the total market share in 2024, dominating the sample category. Monkeypox is characterized by visible skin lesions, including rashes, pustules, and scabs, which contain high concentrations of the virus. These lesions make skin samples the most effective for diagnosis. Diagnostic tools like PCR work well with skin lesion specimens, making them the preferred choice for identifying the virus.
Regional Insights
North America: Leading the Market
North America is set to dominate the monkeypox diagnosis market, holding around 41% of the market share in 2024. This region benefits from robust healthcare infrastructure, substantial investments in medical research, and a high demand for diagnostic solutions. Furthermore, the prevalence of monkeypox, coupled with increased awareness about the disease and vaccination efforts, is expected to drive further market growth in the region.
Europe and Asia-Pacific: Emerging Markets
Europe and the Asia-Pacific region are also expected to see substantial growth, driven by rising awareness, improved healthcare systems, and the integration of monkeypox testing into broader infectious disease panels. These regions are investing in public health surveillance and diagnostics, which will contribute to a higher demand for effective diagnostic solutions.
Competitive Landscape
The monkeypox (mpox) diagnosis market is competitive, with several global and regional players actively contributing to market growth. Major players in the market include Roche, Abbott Laboratories, Cepheid, and Thermo Fisher Scientific. These companies have strong portfolios of molecular diagnostic tests, and their global distribution networks allow them to reach diverse markets effectively.
In addition to large multinational players, several smaller biotech firms and startups are innovating in the development of rapid antigen tests and multiplex assays, which are becoming increasingly important for diagnosing multiple infectious diseases, including monkeypox. The competition is further driven by ongoing R&D initiatives, strategic partnerships, acquisitions, and expanding global reach to cater to growing demand.
Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/34755
Key Players
Some of the key players in the monkeypox (mpox) diagnosis market include:
Abbott Laboratories
Aegis Sciences Corporation
Applied DNA Sciences, Inc.
Becton, Dickinson and Company
BioGX
bioMérieux SA
Bio-Rad Laboratories, Inc.
CerTest Biotec
Quest Diagnostics, Inc.
Thermo Fisher Scientific Inc.
These companies are focusing on advancing diagnostic technologies, acquiring approvals for new diagnostic tests, and expanding their portfolios to address the growing need for rapid and accurate monkeypox detection.
Recent Developments
Several significant developments have shaped the monkeypox (mpox) diagnosis market in recent years:
September 2022: Quest Diagnostics received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its laboratory-developed molecular diagnostic test, enhancing the accessibility and reliability of monkeypox testing.
June 2022: CerTest Biotec and Becton, Dickinson, and Company partnered to develop a molecular diagnostic test for detecting the monkeypox virus, further expanding the market for rapid and reliable diagnostic solutions.
Market Segmentation
The monkeypox (mpox) diagnosis market is segmented by diagnostic test type and sample type:
By Diagnostic Test: Molecular tests, including PCR-based tests, dominate the market due to their high sensitivity and accuracy. Antigen detection tests, while growing, hold a smaller share.
By Sample Type: Skin lesion specimens lead the market due to their high viral load, followed by urine and whole blood samples, which are less commonly used in routine testing.
Future Outlook
The monkeypox (mpox) diagnosis market is poised for steady growth as technological advancements continue to enhance diagnostic capabilities. While the market saw a surge during the outbreaks of 2022 and 2023, the demand for accurate and rapid diagnostic tools is expected to remain strong due to global awareness and surveillance initiatives.
The future growth of the market will likely be influenced by the development of more sophisticated diagnostic tools, including multiplex assays that can detect multiple pathogens simultaneously. Additionally, the expansion of POCT solutions will allow for faster diagnosis, particularly in remote or resource-limited settings.
As the global healthcare system adapts to the challenges posed by infectious diseases, the monkeypox diagnosis market will continue to evolve. The integration of monkeypox testing into broader infectious disease panels, coupled with ongoing investments in diagnostic R&D, will support the market’s long-term growth trajectory.
In conclusion, the monkeypox (mpox) diagnosis market is experiencing dynamic growth driven by technological advancements, rising awareness, and the urgent need for accurate diagnostic solutions. With continued investment in research and development, as well as increased global collaboration, the market is well-positioned to meet the challenges of future outbreaks and play a crucial role in global public health preparedness.
